Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus

OBJECTIVE: Evaluate the efficacy and safety of ustekinumab, an anti-interleukin-12/23 p40 antibody, in a phase 3, randomised, placebo-controlled study of patients with active systemic lupus erythematosus (SLE) despite receiving standard-of-care. METHODS: Active SLE patients (SLE Disease Activity Ind...

Descripción completa

Detalles Bibliográficos
Autores principales: van Vollenhoven, Ronald F, Kalunian, Kenneth C, Dörner, Thomas, Hahn, Bevra H, Tanaka, Yoshiya, Gordon, Robert M, Shu, Cathye, Fei, Kaiyin, Gao, Sheng, Seridi, Loqmane, Gallagher, Patrick, Lo, Kim Hung, Berry, Pamela, Zuraw, Qing C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Systemic Lupus Erythematosus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606504/
https://www.ncbi.nlm.nih.gov/pubmed/35798534
http://dx.doi.org/10.1136/ard-2022-222858

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606504/
https://www.ncbi.nlm.nih.gov/pubmed/35798534
http://dx.doi.org/10.1136/ard-2022-222858

Ejemplares similares